Sign in →

Test ID NBLD0570 JAK2 Exon 12 and Other Non-V617F Mutation Detection, Bone Marrow

Useful For

Second-order testing to aid in the distinction between a reactive cytosis and a myeloproliferative neoplasm, particularly when a diagnosis of polycythemia is being considered, using bone marrow specimens

Specimen Type

Bone Marrow


Ordering Guidance


For cases being evaluated for JAK2 mutation status, the initial test that should be ordered is JAK2M / JAK2 V617F Mutation Detection, Bone Marrow, a sensitive assay for detection of the mutation. However, if no JAK2 V617F mutation is found, further evaluation of JAK2 may be clinically indicated.



Shipping Instructions


1. Specimen must arrive within 5 days (120 hours) of collection.

2. Collect and package specimen as close to shipping time as possible.



Necessary Information


Date of collection is required.



Specimen Required


Container/Tube:

Preferred: EDTA (lavender top)

Acceptable: ACD (yellow top)

Specimen Volume: 4 mL

Collection Instructions:

1. Invert several times to mix bone marrow.

2. Send bone marrow specimen in original tube. Do not aliquot.


Specimen Minimum Volume

2 mL

Reject Due To

Gross hemolysis Reject
Moderately to severely clotted Reject

Specimen Stability Information

Specimen Type Temperature Time Special Container
Bone Marrow Refrigerated (preferred) 5 days PURPLE OR PINK TOP/EDTA
  Ambient  5 days PURPLE OR PINK TOP/EDTA

Day(s) Performed

Monday through Saturday

Report Available

5 to 8 days

Method Name

Sanger Sequencing

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

0027U-JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence and exon 13 sequence, if performed

Reporting Name

JAK2 Exon 12 Mutation Detection, BM

Testing Algorithm

This is a second-order test that should be used when the test for the JAK2M / JAK2 V617F Mutation Detection, Bone Marrow test is negative.

 

See Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation.

Reference Values

An interpretive report will be provided.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

Secondary ID

60025

Forms

1. Hematopathology Patient Information (T676)

2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.

Sanford Laboratories - Fargo Additional Information:

SANFORD INTERFACE BUILD INFORMATION

Result Code Result Code Description
21732 JAK2 Sequencing Result
21733 Final Diagnosis